98095-37-5

Basic information

• Product Name: 4-(2-iodoethyl)-2,2-dimethyl-1,3-dioxolane
• Synonyms: 4-(2-iodoethyl)-2,2-dimethyl-1,3-dioxolane
• CAS NO: 98095-37-5
• Molecular Weight: 256.084
• Mol File: 98095-37-5.mol
• Article Data: 18

Chemical Properties

• CAS DataBase Reference: 4-(2-iodoethyl)-2,2-dimethyl-1,3-dioxolane(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-iodoethyl)-2,2-dimethyl-1,3-dioxolane(98095-37-5)
• EPA Substance Registry System: 4-(2-iodoethyl)-2,2-dimethyl-1,3-dioxolane(98095-37-5)

Safety Data

• Hazardous Substances Data: 98095-37-5(Hazardous Substances Data)

Upstream product

• 453-20-3 3-Hydroxytetrahydrofuran 
• 67-64-1 acetone 
• 83470-62-6 methanesulfonic acid 2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-ethyl ester 
• 94992-56-0 (S)-1,2-O-isopropylidene-4-O-<(4-methylphenyl)sulfonyl>-1,2,4-butanetriol 
• 32233-43-5 2-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]ethanol 
• 95422-24-5 methyl (3S)-3,4-O-isopropylidene-3,4-dihydroxybutanoate 
• 42890-78-8 (S)-(-)-isopropylidenedioxybutyl bromide 
• 97-67-6 (S)-Malic acid 

Downstream Products

• 1178541-00-8 (R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyloxime 
• 1178540-43-6 (R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydro-2-[14C]-pyrido[4,3-d]pyrimidin-5(6H)-one O-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl oxime 
• 1436382-65-8 (S)-4-O-(2-hydroxy-4-nitrophenyl)-1,2-O-isopropylidene-1,2,4-butanetriol 
• 1376191-48-8 (S)-4-(4-chlorophenyl)-1-[2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl]-N-[3-(4-methylpiperazin-1-yl)propyl]-3-{4-[4-(4-nitrophenyl)piperazin-1-yl]phenyl}-1H-pyrrole-2-carboxamide 
• 1376191-39-7 (S)-ethyl 4-(4-chlorophenyl)-1-[2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl]-3-(4-iodophenyl)-1H-pyrrole-2-carboxylate 
• 1376190-98-5 (S)-ethyl 4-(4-chlorophenyl)-1-[2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl]-3-(3-iodophenyl)-1H-pyrrole-2-carboxylate 
• 1376190-88-3 (S)-ethyl 4-(4-chlorophenyl)-1-[2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl]-3-phenyl-1H-pyrrole-2-carboxylate 
• 1314887-12-1 (S)-methyl 4-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-phenylbutanoate 
• 101-41-7 benzeneacetic acid methyl ester 
• 1253597-06-6 2,2-dimethyl-4-(5-phenylpentyl)-1,3-dioxolane 
• 1154488-42-2 (S)-ethyl 2-(3,4-dimethoxyphenyl)-4-(2,2-dimethyl-1,3-dioxolan-4-yl)butanoate 
• 119435-06-2 (1S,5S)-5-(2-Benzyloxy-ethyl)-6,8-dioxa-bicyclo[3.2.1]octane 
• 119385-25-0 [(2S,6R)-6-(2-Benzyloxy-ethyl)-tetrahydro-pyran-2-yl]-methanol 
• 119385-26-1 (2R,6R)-2-(2-Benzyloxy-ethyl)-6-methyl-tetrahydro-pyran 

Relevant articles and documents

6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER

The present invention discloses 6,7-dihydro-5H-pyrido[2,3- c]pyridazine, 1,2,3,4-tetrahydroquinoline, 1H-indole, 3,4- dihydro-2H-1,4-benzoxazine, 1H-pyrrolo[2,3-b]pyridin-1-yl, 7H- pyrrolo[2,3-c]pyridazine, 5H,6H,7H,8H,9H-pyridazino[3,4-b]azepine derivatives and related compounds of formula (I) as Bcl-xL protein inhibitors for use as pro-apoptotic agents for treating cancer, autoimmune diseases or immune system diseases. Formula (I). The description discloses the preparation of exemplary compounds (e.g. pages 113 to 354 examples 1 to 221) as well as pharmacological studies with relevant data (e.g. pages 355 to 367; examples A to E; tables 1 to 5). Exemplary compounds are e.g. 2-{6-[(1,3-benzothiazol-2-yl) amino]-1,2,3,4-tetrahydroquinolin-1-yl}-1,3-thiazole-4-carboxylic acid (example 1) or e.g. 3-{1-[(adamantan-1-yl)methyl]-5- methyl-1H-pyrazol-4-yl}-6-{3-[(1,3-benzothiazol-2-yl)amino]-4- methyl-5H,6H,7H,8H-pyrido[2,3-c]pyridazin-8-yl]pyridine-2-carboxylic acid (example 24).

Synthesis of non-hydrolysable mimics of glycosylphosphatidylinositol (GPI) anchors

Synthesis of first generation non-hydrolysable C-phosphonate GPI analogs, viz., 6-O-(2-amino-2-deoxy-α-d-glucopyranosyl)-d-myo-inositol-1-O-(sn-3,4- bis(palmitoyloxy)butyl-1-phosphonate) 23a and 6-O-(2-amino-2-deoxy-α-d- glucopyranosyl)-d-myo-inositol-1-O-(sn-2,3-bis(palmitoyloxy)propyl-1- phosphonate) 23b, is reported. The target compounds were synthesized by the coupling of α-pseudodisaccharide 21 with phosphonic acids 18a and 18b respectively in quantitative yield followed by de-protection. These synthetic C-phosphonate GPI-probes were resistant to phosphatidylinositol specific phospholipase C (PI-PLC) and also showed moderate inhibition of the enzyme activity. The Royal Society of Chemistry.

The first total synthesis of cytopiloyne, an anti-diabetic, polyacetylenic glucoside

The first total synthesis of cytopiloyne 1, a novel bioactive polyacetylenic glucoside isolated from the extract of Bidens pilosa, is described. The structure of cytopiloyne was determined to be 2-β-D-glucopyranosyloxy-1-hydroxytrideca-5,7,9,11-tetrayne by using various spectroscopic methods, but the chirality of the polyyne moiety was unknown. Herein, the convergent synthesis of two diastereomers of cytopiloyne by starting from commercially available 4-(2-hydroxyethyl)-2,2-dimethyl-1,3-diozolane is described. The synthetic sequence involved two key steps: stereoselective glycosylation of the glucosyl trichloroacetimidate with 1-[(4-methoxybenzyl)oxy] hex-5-yn-2-ol to give the desired β-glycoside and the construction of the glucosyl tetrayne skeleton by using a palladium/silver-catalyzed cross-coupling reaction to form the alkyne-alkyne bond, the first such use of this reaction. Comparison between the observed and published characterization data showed the 2R isomer to be the natural product cytopiloyne.